Tesaro v Myriad: Niraparib partners squared off in court as Tesaro tried to quash a contrary press release
When Tesaro released their data on the PARP drug niraparib a few days ago, the biotech was determined to make a case for a broad approval, without any need for a diagnostic test to distinguish patients with a particular biomarker for ovarian cancer.
Not everybody, of course, bought in to that argument, with some critics saying that the data were iffy at best. One key objection, though, came from Myriad Genetics, which developed the companion diagnostic test Tesaro used in Phase III and now wants to see put into use. And Tesaro wound up taking them to court in a failed attempt to shut it down.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.